DNA repair deficiency biomarkers identify HR+/HER2- breast cancer patients who may benefit from veliparib/carboplatin: results from the I-SPY 2 TRIAL

Author(s): L. van 't Veer, L. Esserman, A. Sanil, A. Glas, T. Severson, S. Linn, L. Brown-Swigart, G. Hirst, I-SPY 2 TRIAL Investigators, O. Olapade, H .Rugo, D. Berry, D. M. Wolf, and C. Yau

Background In I-SPY 2, HER2- patients were adaptively randomized to receive standard chemotherapy or the PARP inhibitor veliparib with carboplatin (V/C) and chemotherapy. V/C graduated in the triple-negative (TN) subtype, and we have previously shown that DNA repair deficiency signatures [PARPi-7 and BRCAness] … Continued

Functional Subtyping with BluePrint 80-gene profile identifies distinct triple positive subtypes with and without trastuzumab/pertuzumab/chemo-sensitivity

Author(s): Pat Whitworth, Peter Beitsch, Paul Baron, Michael C Rotkis, James V Pellicane, Mary Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Jennifer Beatty

Background and Aim Classification into molecular subtypes is important for the selection of therapy for patients with breast cancer. Previous analyses demonstrated that breast cancer subtypes have distinct clinical outcome (Glück, BCRT 2013). The aim of the prospective NBRST study is to compare a … Continued

Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups

Publication Name: Cancer Research

Author(s): Massimo Cristofanilli, Karen Kaul, Mary Turk, JoEllen Weaver, Jelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Katharine Yao

This retrospective study showed that Molecular Subtyping of early breast cancers using Mammaprint and BluePrint leads to reclassification of 25% (51/208) of tumors with potential therapeutic and prognostic implications: – 39% of clinical HER-2 disease should have been treated with … Continued

PROMIS – PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score

Publication Name: Cancer Research

Author(s): Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

PROMIS is a prospective study that will investigate the additional value of MammaPrint, BluePrint and TargetPrint in women with an intermediate Oncotype DX score. An initial CRF – capturing baseline patient characteristics, pathology information, Oncotype DX score and the recommended … Continued

MINT I – Multi-Institutional Neoadjuvant Therapy, MammaPrint Project I

Publication Name: Cancer Research

Author(s): Charles Cox, Peter Blumencranz, Douglas Reintgen, Ruben Saez, Nicole Howard, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück

Treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy measures the in vivo response to chemotherapy,1 assesses long-term clinical outcomes associated with that response2,3 and enables some patients to undergo breast-conservation therapy due to therapeutic down-staging of the tumor.  In the current study, the … Continued

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer

Publication Name: Cancer Research

Author(s): C.A. Drukker, M.V. Nijenhuis, S.G.Elias, J. Wesseling, N.S. Russell, P. Whitworth, R. Patel, F. de Snoo, L.J. van’t Veer, P.D. Beitsch, E.J.Th. Rutgers

The 70-­‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-­‐gene signature result compared to those with high risk 70-­‐gene signature result, independent … Continued

Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Publication Name: SABCS 2012 Poster

Author(s): Giuseppe Viale, Leen Slaets, Femke de Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Lisette Stork-Sloots, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified.  Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to … Continued

Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer

Publication Name: 2012 ASCO Gastrointestinal Cancers Symposium, JCO Abstract

Author(s): Josep Tabernero, Victor Moreno, Robert Rosenberg, Ulrich Nitsche, Thomas Bachleitner-Hofmann, Giovanni Lanza, Jeroen van den Akker, Paul Roepman, Iris Simon, Ramon Salazar; Vall d'Hebron University Hospital, Barcelona, Spain; IDIBELL, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Medizinische Universitaet Wien, Vienna, Austria; Department of Experimental and Diagnostic Medicine, Section of Anatomic Pathology, Ferrara, Italy; Agendia BV, Amsterdam, Netherlands; Institut Catala d'Oncologia, Barcelona, Spain

Background: Between 25 and 35% of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy. ColoPrint is a gene expression classifier that can predict disease relapse in patients with early-stage colorectal … Continued

Response to neo-adjuvant chemotherapy and outcomes for I-SPY 1 patients stratified by the 70-gene prognosis signature (MammaPrint) and molecular subtyping (BluePrint)

Publication Name: Cancer Research, Poster

Author(s): Stefan Glück, Femke de Snoo, Sun Tian, Annuska Glas, Laura van 't Veer

Classification of breast cancers into molecular subtypes may be important for the proper selection of therapy for patients as tumors with seemingly similar biology can have strikingly different clinical outcomes. The multi-center neo-adjuvant I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) … Continued

A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites

Publication Name: ASCO 2011 Poster

Author(s): W. Zwart, F. De Snoo, et al

Classification of breast cancer into molecular subtypes may be important for the proper selection of therapy, as tumors with seemingly similar biology can have strikingly different clinical outcomes. We have previously developed an 80-gene molecular subtyping profile (BluePrint) for the classification of breast cancer into three … Continued